- Lufax Holding is now the target of multiple securities class action lawsuits in the US, following allegations of inadequate internal controls, undisclosed related-party transactions, and materially misstated financial results, as well as the removal of auditor PricewaterhouseCoopers over concerns about its 2022 and 2023 reports.
- An unusual aspect of this situation is the rare withdrawal of PwC’s prior audit opinions, prompting several law firms to pursue claims on behalf of investors who bought Lufax securities between April 7, 2023 and January 26, 2025.
- We’ll now examine how the auditor’s removal and related-party transaction concerns may reshape Lufax Holding’s investment narrative for investors.
Invest in the nuclear renaissance through our list of 93 elite nuclear energy infrastructure plays powering the global AI revolution.
What Is Lufax Holding's Investment Narrative?
Lufax is now a turnaround story that hinges on whether investors still trust the numbers. Before PwC’s rare withdrawal of its 2022 and 2023 audit opinions, the core debate was already about shrinking revenue, a swing to a CN¥3,870.62 million loss in 2024, and whether a low price to sales multiple could offset those pressures. The new class actions and related party transaction concerns push governance and balance sheet transparency right to the top of the risk list, at least in the near term. Short term catalysts such as a path back to profitability, tighter risk control in consumer lending, and a relatively new management team bedding in now sit in the shadow of audit restatements, potential regulatory scrutiny, and any impact on access to capital.
However, the real test for shareholders may be how deep the internal control issues ultimately run. Our valuation report here indicates Lufax Holding may be undervalued.Exploring Other Perspectives
Three Simply Wall St Community fair value estimates cluster between US$1.81 and about US$2.99 per share, even as recent lawsuits, auditor changes and accounting questions keep pulling attention back to Lufax’s core operational risks and future resilience. This spread of views shows how differently people are weighing governance concerns against any potential recovery in the underlying business, so it is worth comparing several of these perspectives before drawing your own conclusions.
Explore 3 other fair value estimates on Lufax Holding - why the stock might be worth as much as 61% more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Lufax Holding research is our analysis highlighting 2 key rewards that could impact your investment decision.
- Our free Lufax Holding research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Lufax Holding's overall financial health at a glance.
Ready To Venture Into Other Investment Styles?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
- We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com